title: [Utrogestan--an alternative for synthetic gestagen treatment in spontaneous abortion].
abstract: A clinical trial is conducted with 32 pregnant patients with a history of sterility and infertility, uterine malformations as well as progesterone deficiency. The mean week of gestation is 9-10. All patients were treated with Utrogestan in the usual doses 2 x 100 mg for vaginal application. No side effects were observed which is encouraging to its routine use.
authors.forename: B
authors.initials: B
authors.lastname: Nalbanski
authors.forename: K
authors.initials: K
authors.lastname: Tsekova
authors.forename: S
authors.initials: S
authors.lastname: Ivanov
authors.forename: I
authors.initials: I
authors.lastname: Kostov
mesh_terms: D000022:Abortion, Spontaneous / Q000517:prevention & control*; D000282:Administration, Intravaginal; D000284:Administration, Oral; D005260:Female; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011374:Progesterone / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D045167:Progesterone Congeners / Q000627:therapeutic use*; D011980:Receptors, Progesterone / Q000819:agonists; D014018:Tissue Distribution
chemical_list: D045167:Progesterone Congeners; D011980:Receptors, Progesterone; D011374:Progesterone